Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Could Moderna Take Down Gilead Sciences?

TheMotleyFool

0 0

Could Moderna Take Down Gilead Sciences?Photo, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png

Juggernaut. There's probably no better word to describe the position of Gilead Sciences (NASDAQ: GILD) in the HIV therapy market. The big biotech has dominated for two decades with its antiviral drugs.

Gilead still has formidable rivals in treating HIV. GlaxoSmithKline and Johnson & Johnson also market HIV therapies. But they haven't been successful in dethroning Gilead.

Now another competitor is on the scene. Moderna (NASDAQ: MRNA) became a household name -- and one of the hottest biotech stocks on the market -- with its messenger RNA (mRNA) COVID-19 vaccine. The biotech will soon begin clinical testing of a new vaccine candidate targeting HIV. Could Moderna take down Gilead Sciences?

Source Fool.com

Like: 0

MRNA

Share